ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer.

Saulo Fm da Silva, Eddie Fc Murta, Márcia A Michelin

Immunotherapy 2024 Feb

filter terms:

Objective: To evaluate the behavior of adhesion molecules ICAM-1 and ICAM-2 in dendritic cell (DC) immunotherapy. Materials & methods: 88 female Balb/c mice were divided into experimental groups. Tumors and lymph nodes were evaluated 7 and 14 days after immunotherapy. Results: Higher mean fluorescence intensity of ICAM-1 in the lymph nodes and tumors in the tumor group at 14 days was observed. Higher mean fluorescence intensity of ICAM-2 in the tumor DC vaccine group was observed after 14 days. A positive correlation was observed in the lymph nodes with ICAM-1 against tumoral volume in the tumor group. A negative correlation was found between ICAM-2 and tumoral volume in the lymph nodes of the tumor group. Conclusion: An increase in ICAM-2 in tumor DC vaccine and a decrease in ICAM-1 suggests the DC vaccine positively influences the immune system and that ICAM-2 could be a marker of good prognosis.

Citation

Saulo Fm da Silva, Eddie Fc Murta, Márcia A Michelin. ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer. Immunotherapy. 2024 Feb;16(3):173-185